This study will measure brain glutathione using non- invasive, state-of-the-art MEGA-PRESS pulse sequence in pre and post GGC supplementation after 12 months. The GSH level will also be measured in the blood in pre and post GGC supplementation. Brain and blood iron level will be measured in pre and post GGC supplementation.
The neuropsychological examination and motor function will be performed in pre and post GGC supplementation.
This study will provide the relation of brain GSH enrichment with motor performance.
Our study will also provide any possible correlation with reduction of dysbiosis of the gut microbiome with GSH enrichment.
Age
50–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed Parkinson's Disease diagnosis.
Montreal Cognitive Assessment (MoCA) greater than or equal to 26.
Age (50 to 80 years of age).
Ability to read and write in English.
You may not be if
Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body.
Subjects with claustrophobia.
Patients with a clinical diagnosis of Parkinson's disease dementia or dementia with Lewy bodies.
Subjects with a history of cancer.
Subjects with active psychosis or delirium.
Subjects with chronic kidney (creatinine \> 1.5mg/dL) or liver disease (AST ≥ 1.5 ULN; ALT ≥ 1.5 ULN) within 30 days prior to enrolment.
Subjects on antioxidant therapy (ashwagandha, gingko biloba or N-acetylcysteine) or illicit drug abuse/dependence (cocaine, heroin, marijuana, or fentanyl).
Subjects with previous traumatic head injury.
Clareo Health | Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
